Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTx001 · 1 trial · 1 indication
Incidence and severity of ocular and non-ocular adverse events (AE)s and serious AEs (SAEs) up to Week 52 (Year 1)
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Low Dose |
| Cohort 2 | EXPERIMENTAL | Medium Dose |
| Cohort 3 | EXPERIMENTAL | High Dose |
| Cohort 4 | EXPERIMENTAL | Expansion of a dose selected from Cohort 1-3 |
| Cohort 5 | EXPERIMENTAL | Expansion of a second dose selected from Cohort 1-3 |
| Name | Type | Description |
|---|---|---|
| CTx001 | GENETIC | Subretinal administration of CTx001 |
Inclusion Criteria: Meet protocol-defined age eligibility Have bilateral geographic atrophy secondary to AMD, confirmed by the Reading Center Meet baseline lesion size requirements, as assessed by fundus autofluorescence imaging Meet best-corrected visual acuity and low-luminance visual acuity c...
CTx001 is an investigational gene therapy being developed for the treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The therapy is being studied in a controlled clinical trial to evaluate its safety and efficacy.
CTx001 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting a Phase 1 clinical trial of CTx001 for Geographic Atrophy Secondary to Age-related Macular Degeneration.
CTx001 is currently in Phase 1 clinical development. It is an investigational gene therapy and has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants to assess the safety and potential efficacy of the treatment.
CTx001 is being evaluated in a Phase 1 clinical trial with the identifier NCT07392255, titled "An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)." The trial is recruiting 75 participants in the United States and United Kingdom.
Yes, CTx001 is a gene therapy being developed for Geographic Atrophy Secondary to Age-related Macular Degeneration. It is currently in Phase 1 clinical trials, where it is being tested in a controlled study to determine if the treatment is safe and effective for patients with this condition.